Medetomidine
Founded in 2017, Sigma Chemical Co., Ltd. supplies over 100 countries with high-quality chemicals. We are dedicated to safety, innovation, and global cooperation.
Product Description
Medetomidine is a potent, selective α₂-adrenergic receptor agonist primarily employed in veterinary medicine as a sedative, analgesic, and premedication agent, existing as a racemic mixture of enantiomers with dexmedetomidine as the active isomer approved for human clinical use. While traditionally valued for inducing profound sedation and pain relief in animals, as evidenced by its role in anesthetic protocols and a reported case of accidental coadministration with vatinoxan and ketamine in a cat leading to tachycardia and excitement, medetomidine has recently emerged as a dangerous adulterant in the U.S. illicit drug supply, with NFLIS reports surging from 245 in 2023 to 2,276 in 2024—predominantly in the Northeast—and co-reported with fentanyl in over 63% of cases, exacerbating overdose risks through severe cardiovascular depression. Beyond these contexts, medetomidine and its analogues, such as the superior MM-4 variant, are increasingly integrated into epoxy-based marine coatings for antifouling and anticorrosion properties, effectively inhibiting barnacle settlement, bacterial biofilms, and algal growth while maintaining high impedance against seawater corrosion for up to 90 days; paradoxically, it promotes larval attachment in invasive ascidians like Botrylloides violaceus but inhibits their metamorphosis, highlighting its nuanced potential in ecological fouling control.
Synthesis and Production
Medetomidine is synthesized through various organic chemistry methods, often as a racemic mixture of dexmedetomidine (active enantiomer) and levomedetomidine. The first reported synthesis, disclosed in a 1981 patent by Farmos Group Ltd. and published in 1983, involves sequential Grignard reactions. The process starts with a Grignard reagent addition to form a tertiary alcohol intermediate, followed by dehydration and hydrogenation to yield medetomidine hydrochloride in 17% overall yield. Additional routes have been developed to improve yield, scalability, and avoid toxic reagents, including:
-
Nucleophilic addition of 1-trityl imidazole-4-formaldehyde with 2,3-dimethyl phenylmagnesium bromide, followed by deprotection.
-
Halogenated imidazoles undergoing transmetalation with Grignard reagents, then reaction with 2,3-dimethyl benzaldehyde.
-
Reduction of 2,3-dimethyl acetophenone with NaBH4 to form 1-(2,3-dimethylphenyl)ethanol, followed by reaction with titanium tetrachloride and 1-(trimethylsilyl)-1H-imidazole (overall yield ~75%).
Commercially viable processes combine classical imidazole ring formation (e.g., copper(I) medetomidine complex decomplexation) with reliable approaches, often involving chiral resolution or stereoselective hydrogenation using chiral phosphine ligands for dexmedetomidine enrichment (enantiomeric excess up to high levels, with recycling of undesired isomers). Medetomidine was developed by Farmos Group Ltd. (later Orion Pharma) and launched in 2007. Production is multi-step, focusing on hepatic biotransformation analogs, and is not detailed for large-scale manufacturing due to proprietary patents. It is typically prepared as the hydrochloride salt (white solid, mp 175.5–178.5°C).
Uses and Applications
Medetomidine is primarily used in veterinary medicine for its sedative, analgesic, and anxiolytic properties. It is approved for use in animals, including dogs over 12 weeks, cats, sheep, and horses off-label. It is marketed as Domitor (racemic mixture) by Pfizer Animal Health in the US and Novartis in Canada. It induces profound sedation with preserved respiratory drive and is reversed by atipamezole. In wildlife management and conservation, it is combined with ketamine for immobilizing large felids like jaguars during clinical evaluations, semen collection, and echocardiography.
In human applications, the active enantiomer, dexmedetomidine (Dexdor/Precedex), is FDA-approved for ICU sedation in intubated/mechanically ventilated patients, analgesia, and non-intubated procedures. It is used for sedation in intensive care and procedural settings due to its favorable pharmacodynamic profile, including dose-dependent sedation, anxiolysis, and sympatholytic effects with minimal respiratory depression.
Marine antifouling: As the free base (Selektope), it is an environmentally friendly agent in coatings to prevent barnacle and hard fouling settlement on ship hulls and structures. It induces hyperactivity in barnacle cyprid larvae via octopamine receptor interaction, causing increased kicking and reversible prevention of attachment.
Illicit and emerging uses: Medetomidine has been detected as an adulterant in the unregulated drug supply since 2022, often mixed with fentanyl, xylazine, cocaine, heroin, or methamphetamine. It potentiates sedative/euphoric effects of opioids, leading to heavy sedation but increases overdose risks. It has been detected in up to 61% of dope samples in Pennsylvania (2024), co-reported with fentanyl in >63% of NFLIS cases, surging from 245 reports (2023) to 2,276 (2024), primarily in the Northeast.
Properties and Characteristics
Medetomidine is a racemic mixture of dexmedetomidine (S-enantiomer, pharmacologically active) and levomedetomidine, with the S-isomer twice as potent. Key characteristics include:
-
Potency and Selectivity: 100–300 times more potent than xylazine, with an α2:α1 binding ratio of 1620:1. It centrally decreases noradrenergic activity in the locus coeruleus for sedation and acts centrally/peripherally for analgesia.
-
Pharmacological Effects: Profound sedation, bradycardia, hypotension, and cardiovascular depression. In intoxication: heavy sedation, low blood pressure, slow heart rate, dizziness, extreme tiredness. In withdrawal: tachycardia, hypertension, encephalopathy, vomiting, tremor, hypoactive encephalopathy, and refractory symptoms.
-
Structure-Activity Relationships (SAR): Imidazole linked to 2,3-dimethylbenzene via a methylene bridge with a methyl at the α-position (optimal for potency). Smaller alkyls tolerated but not superior. Removal or hydroxyl substitution reduces activity. S-enantiomer is active. Analogs like MM-4 (dichloro-substituted) show better antifouling and anticorrosion.
-
Metabolism and Pharmacokinetics (DMPK): Rapid hepatic metabolism via hydroxylation (CYPs, e.g., CYP2A6) to 3-hydroxy-medetomidine (3-OH-M) and minor metabolites (carboxylic acid). Elimination primarily renal. Clearance of levomedetomidine is faster (4.07 L/h/kg) than dexmedetomidine. Detected post-glucuronidase treatment in urine (32% exposures missed without it). Half-life and distribution not fully detailed for illicit use.
-
Physical/Chemical: White solid (HCl salt); chiral; SMILES: CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C; InChI: 1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15); InChIKey: CUHVIMMYOGQXCV-UHFFFAOYSA-N.
-
Other: Reversible with atipamezole; no bioaccumulation in benthic invertebrates; induces hyperactivity in barnacles but inhibits ascidian metamorphosis; associated with necrotic skin wounds (less than xylazine); frequent co-adulterant with fentanyl (>50–63% cases).
Safety and Handling
Medetomidine is not approved for human use and poses significant risks as an illicit adulterant. Safety concerns include:
-
Overdose Effects: Heavy sedation, bradycardia, hypotension, CNS depression, respiratory depression (when mixed with opioids), dizziness, extreme tiredness, and hypoxemia. Not reversed by naloxone, requiring supportive care like airway management, supplemental oxygen, and calling 911. In animals: Vomiting (12–65% in dogs/cats), muscle jerking (0.5% in dogs), alveolar damage in sheep.
-
Handling Precautions: Avoid self-injection (especially in pregnant women, as it causes uterine contractions and decreased fetal blood pressure). Can be absorbed through skin/eyes causing irritation. Keep out of reach of children. In veterinary settings, monitor for side effects like muscle weakness, drowsiness. Special precautions for pregnant handlers.
-
Public Health Risks: As an adulterant, it exacerbates the opioid crisis with mass overdoses. Low cost and lack of regulation make it attractive. Detected in seized drugs and toxicological analyses. Associated with severe withdrawal (tachycardia, hypertension, encephalopathy). First responders at risk—use naloxone for suspected opioid involvement but expect incomplete reversal.
-
Toxicity: Activates pulmonary macrophages in sheep, leading to hemorrhage/edema. Reversible in antifouling (no bioaccumulation). Illicit use linked to fatal overdoses and hemodynamic instability.
-
Storage/Disposal: Not specified, but as a veterinary drug, handle per pharmaceutical guidelines.